Skip to main content

FENOTIPOS RELACIONADOS CON LA EVOLUCION CLINICA A CORTO Y LARGO PLAZO EN LA NEUMONIA ADQUIRIDA EN LA COMUNIDAD

PI19/00207

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PRIVADA CLINIC
Execution centre HOSPITAL CLINICO Y PROVINCIAL DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effect of corticosteroids on c-reactive protein in patients with severe community-acquired pneumonia and high inflammatory response, The effect of lymphopenia

  • Torres, Antoni|||0000-0002-8643-2167
  • Ceccato, Adrian|||0000-0001-9454-062X
  • Ferrer, Miguel|||0000-0001-8171-6673
  • Gabarrús, Albert|||0000-0003-3492-1310
  • Sibila, Oriol|||0000-0002-4833-6713
  • Cilloniz, Catia|||0000-0002-4646-9838
  • Méndez, Raúl|||0000-0001-6300-9836
  • Menéndez Villanueva, Rosario|||0000-0002-3592-3839
  • Bermejo Martín, Jesús F.|||0000-0002-7998-6268
  • Niederman, Michael S.
Background: Lymphopenic patients with community-acquired pneumonia (CAP) have shown high mortality rates. Corticosteroids have immunomodulatory properties and regulate cytokine storm in CAP. However, it is not known whether their modulatory effect on cytokine secretion differs in lymphopenic and non-lymphopenic patients with CAP. Therefore, we aimed to test whether the presence of lymphopenia may modify the response to corticosteroids (mainly in C reactive protein (CRP)) in patients with severe CAP and high inflammatory status). Methods: A post hoc analysis of a randomized controlled trial [1] (NCT00908713) which evaluated the effect of corticosteroids in patients with severe CAP and high inflammatory response (CRP.